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Abstract
Blood coagulation factor VIII (FVIII) is a crucial protein cofactor within the blood
coagulation cascade and facilitates the proteolytic activation of factor X by activated factor IX.
During coagulation FVIII is activated and binds, via its C1 and C2 domains, to activated platelet
membranes coordinated by interactions with exposed phosphatidylserine on the membrane
surface. A deficiency of functional FVIII within a patient's bloodstream leads to the blood
disorder hemophilia A, which results in prolonged bleeding episodes. Current treatment for
hemophilia A relies on FVIII replacement therapy via the injection of exogenous FVIII. The main
complication which arises from FVIII replacement therapy is the development of pathogenic
anti-FVIII inhibitory antibodies, which bind to various regions of FVIII disrupting FVIII’s ability to
properly interact with its key binding partners, thereby nullifying treatment.
This thesis reports determination of low resolution SAXS envelopes and progress
towards obtaining atomic resolution molecular structures of full length FVIII in complex with
five different anti-A2 inhibitors, and a human derived anti-C1 inhibitor, NB2E9, in complex with
the lone C1 domain. Solving the structure of one of these complexes would provide insight into
the mechanism of inhibition for the A2 domain that would be invaluable when designing
bioengineered hemophilia A therapeutics. This thesis further reports mutational studies of
FVIII’s C1C2 domains, yielding progress towards identifying docking and undocking
conformations, represented by ~35-45o rotation of the C2 hydrophobic loops. This utilized
designing mutant constructs to form a disulfide bond which locks C1C2 in the proposed
undocking conformation to compare lipid binding affinities, to build our understanding of the
mechanism of lipid association and dissociation.
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Introduction
Hemostasis is the mechanism by which an organism can halt blood loss at the site of
vascular injury while simultaneously maintaining normal blood flow elsewhere in the body.
There are two pieces to the hemostasis mechanism, primary and secondary hemostasis.
Primary hemostasis begins immediately following vascular injury, where bleeding is stopped via
the formation of a hemostatic plug. This plug is constructed of aggregated platelets which
aggregate and bind to the site of injury. Secondary hemostasis refers to the formation of an
insoluble cross-linked fibrin mesh which is incorporated into and around the platelet plug
strengthening and stabilizing the blood clot1. This work focuses on the secondary hemostasis
mechanism, which is driven via protein blood coagulation factors2. These coagulation factors
play crucial roles within the blood coagulation cascade, with a loss of these proteins’ function
leading to blood disorders, more commonly known as hemophilia. Patients who have
hemophilia are unable to properly form blood clots, which leads to potentially life-threatening
bleeding episodes. Specifically, hemophilia A is the result of a deficiency of functional factor VIII
(FVIII), a key coenzyme involved in the intrinsic coagulation cascade. FVIII’s activity is
dependent on its ability to properly interact with several key binding partners and if these
interactions are hindered the result is a loss of function. The work outlined in this thesis focuses
on FVIII.

Primary Hemostasis
During primary hemostasis, a soft plug is formed via platelet aggregation and adhesion
to the site of injury1. This plug then serves as the scaffolding for the congregation of blood
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coagulation factors during secondary hemostasis, where they act to form a more stable hard
fibrin clot2.

Platelet Adhesion
The first step of primary hemostasis begins with the exposure of platelets to the
subendothelial matrix following vascular injury, which triggers the adhesion and activation of
platelets to form a soft clot2. There are multiple receptors on the surface of platelets that play a
role in adhesion, with multiple adhesive proteins interacting with each receptor. Each of these
receptors have regulation mechanisms such that platelet adhesion only occurs following
vascular injury6, 7, 8. Von Willebrand factor (vWF) is a multimeric glycoprotein made up of three
A domains, three B domains, two C domains, and four D domains and mediates platelet
adhesion to exposed vascular sub-endothelium and the subsequent platelet aggregation. Upon
vascular injury, vWF binds to the damaged vessel walls, specifically binding to fibrillar collagen
type I and III via the A3 domain and collagen type VI via the A1 domain 9. Once immobilized,
vWF’s A1 domain binds to platelets via the glycoprotein Ib-IX-V (GPIb-IX-V) receptor complex.
Once bound, the platelets adhere to the exposed collagen of the vessel wall via the
glycoprotein VI receptor (GPVI)8.

Platelet Aggregation
Once bound to the vessel walls via vWF, the platelets begin to aggregate through
platelet-platelet interactions. This occurs following a conformational shift in the integrin αIIbβ3
receptor, which allows for the receptor to bind to fibrinogen resulting in platelet aggregation11.
Additionally, during this process platelets are activated, during which scramblase acts to flip
2

negatively charged phosphatidylserine between the platelet lipid bilayers. This results in an
increase in the negative charge in the outer leaflet of platelet membranes12. These activated
platelet membranes then serve as a surface for secondary hemostasis to form a fibrin clot via
the blood coagulation factors.

Secondary Hemostasis
Secondary hemostasis refers to the formation of a hard fibrin clot and is traditionally
depicted by the blood coagulation cascade model. The coagulation cascade maps out the series
of protein interactions which lead to the proteolytic activation of clotting factors and ultimately
the cleavage of fibrinogen to fibrin to form a hard fibrin clot. This catalytic cascade is divided
into the extrinsic and intrinsic pathways which join at a common pathway11 (Figure 1).
However, this model is insufficient in describing the dynamic nature of these
subsections as they act within the overarching coagulation cascade. To account for this, a cellbased model which breaks the coagulation cascade into three distinct but overlapping phases:
initiation, amplification, and propagation, has been developed to account for the dynamic
nature of this mechanism11.

3

Figure 1. Blood coagulation cascade. The traditional model for blood coagulation, comprised of
both an intrinsic and extrinsic pathway which converge at a final common pathway, resulting in
the generation of fibrin, leading to the formation of a hard clot. FXIIa then begins an enzymatic
activation cascade, generating FXIa, which generates FIXa. FIXa then forms the intrinsic tenase
complex with its cofactor, FVIIIa (generated during amplification). The extrinsic pathway is
initiated by tissue damage, activating FVII. FVIIa then forms a complex with TF, this TF-FIIA
complex and the tenase complex act to proteolytically cleave and thereby activate FX on the
surface of activated platelets during the final common pathway. The generated FXa then forms
the prothrombinase complex with its cofactor, FVa (generated during amplification), which acts
to generate high amounts of thrombin. The generated thrombin then proteolytically converts
the soluble fibrinogen to the insoluble fibrin which assembles into long fibrils that gather at the
site of vascular injury to provide mechanical support to form a stable, hard blood clot.

Initiation
Primary hemostasis begins with the initiation phase (extrinsic coagulation pathway)
following tissue damage which results in the expression of tissue factor (TF), an integral
membrane protein of endothelial cells. Following TF expression, activated factor VII (FVIIa)
4

quickly binds to the exposed TF14. Keep in mind that FVII is the only coagulation protein that is
regularly found in circulation in its activated form, with approximately 1% of the FVII in the
bloodstream being FVIIa15.This TF-FVIIa complex then acts to activate additional FVII leading to
a positive feedback loop in the formation of the TF-FVIIa complex11. Notably TF is the only
coagulation protein, which is permanently attached to the membrane surface, and so acts to
anchor this complex to the surface of TF-bearing cells17. Thus, the initiation step is localized to
TF-bearing cell surfaces at the site of injury.
Beyond activating additional FVII, the TF-FVIIa complex acts to activate small amounts of
factor IX (FIX) and factor X (FX). Factor V (FV) is then directly activated by FXa; however, this
process occurs slowly and little FVa is recruited. The generated FXa then binds to the few
molecules of its cofactor, FVa, that were generated, forming the prothrombinase complex on
the surface of TF-bearing cells. This prothrombinase complex then proteolytically cleaves
prothrombin generating a small amount of thrombin11 (Figure 2).

5

Figure 2. Phase 1 of secondary hemostasis, initiation. Secondary hemostasis is divided into
three distinct, yet overlapping phases: initiation, amplification, and propagation. Initiation
begins following tissue damage, which results in the activation of FVII and platelets. Tissue
factor, located on the surface membrane of endothelial cells binds to FVIIa, the resulting FVIIaTF complex activates small amounts of FIX, FX and FVII. Activated platelets bind to collagen and
activate FV, leading to the formation of the prothrombinase complex (FXa and FVa) on the
surface of TF-bearing cells. Prothrombinase then produces small amounts of thrombin, which is
used during the amplification phase.

Amplification
During the second phase of secondary hemostasis, amplification, the thrombin
generated during the initiation phase diffuses away from the TF-bearing cells and acts to
activate factors V, VIII and XI. Additionally, the thrombin binds to and further activates
platelets, causing an increase in the negative phosphatidylserine headgroups on platelet
membrane surfaces19 (Figure 3). This activation of the blood coagulation factors, and platelet
membranes generates all the necessary components to begin the large-scale thrombin
production seen in the final phase, propagation.
6

Figure 3. Phase 2 of secondary hemostasis, amplification. During amplification, the thrombin
generated during the initiation phase diffuses away from the TF-bearing cells where it
originated and acts to generate FVa, FVIIIa, FXIa, and activated platelets. These activated
coagulation factors and platelets are then utilized for large-scale thrombin recruitment during
the final stage, propagation.

Propagation
The third phase, propagation, occurs on the surface of the newly activated platelet
membranes. This phase is also known as the intrinsic pathway within the blood coagulation
cascade. During the propagation phase large bursts of thrombin are produced, which then
convert the soluble plasma protein fibrinogen into insoluble fibrin. This fibrin is then crosslinked
together and congregates at the site of injury to form an insoluble fibrin mesh that adds
mechanical strength to the soft clot formed during primary hemostasis20.
The protein coagulation interactions which drive this process begins with the contact of
factor XII (FXII) to the negatively charged activated platelet membrane resulting in FXII being
activated (FXIIa), which then activates FXI. FXI is also activated by thrombin in the presence of a
negatively charged surface, as well as being activated by FXIa in a positive feedback loop21. FXIa
then activates FIX22. Thrombin also activates FVIII which acts as a cofactor for the serine
7

protease FIXa, both of which associate to negatively charged platelet membranes and bind to
one another, forming the intrinsic Xase (tenase) complex. This complex proteolytically cleaves
and activates FX23. Following this, FXa associates to FVa on the activated platelet membrane to
form the prothrombinase complex, which cleaves prothrombin, converting it to thrombin at
large-scale24. The generated thrombin further cleaves the soluble fibrinogen to insoluble fibrin
as well as activates FXIII. FXIIIa then acts to form long crosslinked fibrils of this insoluble fibrin
which congregate at the site of injury, forming the insoluble fibrin mesh, resulting in a stabilized
blood clot82 (Figure 4).

Figure 4. Phase 3 of secondary hemostasis, propagation. Propagation, otherwise known within
the traditional blood coagulation cascade as the intrinsic pathway, is stimulated by vascular
damage, resulting in the activation of FXII. FXIIa then begins an enzymatic activation cascade,
generating FXIa, which generates FIXa. FIXa then forms the intrinsic tenase complex with its
8

cofactor, FVIIIa (generated during amplification), and acts to proteolytically cleave and thereby
activate FX on the surface of activated platelets. FXa then forms the prothrombinase complex
with its cofactor, FVa (generated during amplification), which acts to generate high amounts of
thrombin. The generated thrombin then proteolytically converts the soluble fibrinogen to the
insoluble fibrin which assembles into long fibrils that gather at the site of vascular injury to
provide mechanical support to form a stable, hard blood clot.
Table 1. Blood Coagulation Factors and Associated Proteins
Blood Coagulation Factors
and Associated Proteins

Function

Factor I (fibrinogen)

Precursor to fibrin

Factor II (prothrombin)

Once activated (FIIa/Thrombin) activates FI, FV, FX, FVII,
FVIII, FXI, FXIII, protein C, platelets

Factor III (tissue factor)

Cofactor for FVIIa

Factor IV (calcium)

Required for coagulation factors to bind to phospholipids

Factor V

Cofactor for FX, which when bound forms the
prothrombinase complex

Factor VII

Activates FIX, FX

Factor VIII

Cofactor of FIX, which when bound forms the intrinsic
tenase complex

Factor IX

Activates FX, forms intrinsic tenase complex with FVIII

Factor X

Activates FII, forms prothrombinase complex with FV

Factor XI

Activates FIX

Factor XII

Activates FXI, FVII

Factor XIII

Crosslinks fibrin

von Willebrand factor

Binds to and guards against premature
clearance/proteolytic degradation of FVIII, mediates platelet
adhesion

Protein C

Inactivates FVa and FVIIIa

Protein S

Cofactor for activated protein C

9

Blood Coagulation Factor VIII
FVIII is a glycoprotein expressed in and secreted from both liver sinusoidal cells and
endothelial cells acting as an essential cofactor for FIXa within the blood coagulation cascade. A
lack of functional FVIII results in a reduction of FIXa’s activity by 200,000-fold, causing the blood
coagulation cascade to come to a halt25. The factor FVIII gene, F8, is located on the X
chromosome and is comprised of 186,000 base pairs. The encoded full length FVIII protein is
2332 amino acids long with a domain organization of A1-a1-A2-a2-B-a3-A3-C1-C2, with the A
domains having short spacers (a1, a2, a3) which contain acidic regions with clusters of Asp and
Glu residues. Upon secretion from endothelial cells, but prior to circulation, a portion of the B
domain is cleaved and removed between Arg1313 and Arg1648, resulting in a heterodimer
between the light (a3-A3-C1-C2) and heavy chains (A1-a1-A2-a2-B) of FVIII26 (Figure 5).

Figure 5. A schematic view of FVIII as it moves from its initial construct to its activated form.
First, FVIII is synthesized in endothelial cells forming a single 2332 residue polypeptide chain
with the following domain organization: A1-a1-A2-a2-B-a3-A3-C1-C2. The a1, a2 and a3
10

domains are acidic linker regions. Prior to circulation FVIII is cleaved at Arg1313 and Arg1648
resulting in the formation of a heterodimer between the light (a3-A3-C1-C2) and heavy chains
(A1-a1-A2-a2-B). FVIII is then activated by thrombin which cleaves at Arg372, Arg740 and
Arg1689, resulting in FVIII activation. Modified from Mazurkiewicz-Pisarek et al., 2016

During circulation, the light chain of FVIII is tightly bound via noncovalent interactions to
vWF. vWF acts to maintain FVIII’s stability while in circulation by preventing proteolytic
degradation and premature clearance from the blood stream, while also serving to block nonspecific phospholipid binding. Upon vascular injury, FVIII is proteolytically cleaved by thrombin,
and the remainder of the B domain and a3 spacer are removed, activating FVIII (Figure 5). This
activation leads to the dissociation of FVIIIa from vWF24. Following activation and dissociation
from vWF, FVIIIa associates to activated platelet membranes where it acts as a cofactor for FIXa
in the proteolytic cleavage and subsequent activation of FX24, 29. Following activation by
thrombin FVIIIa is inactivated by activated protein C (APC) and its cofactor protein S. This
inactivation comes about as a result from APC’s cleavage of FVIIIa’s A1 and A2 domains at
Arg336 and Arg56227.

FVIII C Domains
A structure of the B-domain deleted FVIII was first solved in 2008 with a resolution of
3.7 Å. This structure implied a difference in the flexibility of the two C domains. The C2 domain
was found to be more loosely bound to the rest of the overall protein, forming 400 Å2 and 200
Å2 of interfaces between the C1 and A3 domains, respectively, for a total 600 Å2 of total
contact. The C1 domain is more tightly bound, with a 1200 Å2 of hydrophobic interface with the
A3 domain, for a total of 1400 Å2 62. The flexibility of the C2 domain was confirmed in 2020,
11

with the publication of the high-resolution structure of a FVIII therapeutic, ET3i. This structure
was crystalized with two proteins in the asymmetric unit, which allowed for two structures to
be compared. Notably, these two ET3i molecules were in differing conformations dubbed
model A and model B. Model A was in a conformation previously see in literature while a new
conformation was found in model B. The conformation identified in model B was found to have
residues rotated ~35-45 degrees around a central set of core residues, with shifts of individual
residues up to 14 Å45(Figure 6). The flexibility of the C2 domain implies the possibility of two
distinct motifs of FVIII. One in which FVIII binds to activated platelet membranes, and the other
which acts as a non-binding conformation. The C domains of FVIII are structurally homologous
to one another, containing common structural features such as two hydrophobic loops which
extend beyond the overall globular fold at the bottom of the overall protein, and thought to be
involved in lipid binding63. Notably, the affinity of recombinant C2 to phospholipids has been
shown to have an approximate 40-fold decrease when compared to FVIII, suggesting the need
for both C domains for optimal lipid binding64. Mutations of FVIII in any of its domains that
disrupt its ability to function within the blood coagulation cascade can lead to a loss of
functionality of the protein and by extension loss of coagulation ability of the entire cascade.

12

Figure 6. FVIII C2 domain flexibility. A) Structural alignment of FVIII C1 and C2 domains in
proposed docking (model B) and undocking (model A); C1 model A: orange, C1 model B: cyan,
C2 model A: green, C2 model B: purple. B) 90o rotation to the left for side view of the C1
domain alignment. C: 90o rotation to the right for side view of the C2 domain alignment, the C2
domain rotates around a set of central residues, resulting in a shift of the hydrophobic loops
away from the C1 domain. Generated from PDB: 6MF0.

Hemophilia A
A deficiency in functional FVIII in a patient's bloodstream causes a bleeding disorder
known as hemophilia A. Hemophilia A is a hereditary X-linked disorder which results in
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improper blood clot formation, causing heavy bleeding episodes that can result in death.
Approximately 1 in 5,000 males are born with hemophilia A each year. There are many different
mutations of the F8 gene which can lead to varying loss of FVIII function, and thereby
hemophilia A of varying levels of severity. These loss-of-function mutations range from
complete loss of FVIII production, to single point mutations which disrupt FVIII’s ability to
properly interact with key binding partners (such as vWF, FIXa, activated platelet membranes).
The severity of hemophilia A is defined by the residual level of functional FVIII found in a
patient's blood; mild: 6-49%, moderate: 1-5%, severe: <1%26. Strikingly, about 60-70% of
patients with hemophilia A are severe cases32.
Beyond genetic complications, it is possible, although rare, for patients with functional
FVIII to develop anti-FVIII inhibitory antibodies through an autoimmune response. These
antibodies act to neutralize a patient’s endogenous FVIII, causing a decrease in the residual
levels of functional FVIII found in the blood. This results in what is known as acquired
hemophilia A33.

Hemophilia A Treatment
Currently, the main treatment for hemophilia A relies on regular direct infusions of
plasma derived or recombinant FVIII, in a process known as FVIII replacement therapy. The
dosage and frequency of infusion is dependent on the severity of the disorder and can cost in
the in the range of $300,000-$500,000 per year, per patient34, 35. There are alternative drugs for
treating hemophilia A currently available, however the most successful and most employed is
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replacement therapy36. Yet, due to the need for frequent infusion, high cost, and treatment
related complications there is ample opportunity for improvement in hemophilia A treatment.

Treatment Complications: Development of Inhibitory Antibodies
While effective in stopping bleeding episodes, frequent FVIII replacement therapy may
give rise to the development of inhibitory antibodies by a patient's immune system, which act
to neutralize the effect of the injected FVIII. The development of inhibitory antibodies is
relatively common within highly treated patients with approximately 30% of those with severe
hemophilia A developing inhibitory antibodies26. For those individuals who develop this
complication from FVIII replacement therapy, or those with acquired hemophilia A, there are
treatment options available.
Immune tolerance induction (ITI) is the only treatment method proven to work in the
eradication of these inhibitors. ITI involves frequent injection of increasingly high doses of FVIII
concentrate alongside prothrombin complex concentrates to control bleeding episodes, while
trying to re-educate the immune system to tolerate the exogenous FVIII and cease production
of inhibitors. If after 6 months there is not a sustained downward trend in inhibitor
concentration within the blood, immunosuppressants are also prescribed38, 26. While ITI is
successful in 60%-80% of patients it is quite costly and demanding, with an average duration of
treatment of 18.7 months and an average total cost of $1,463,668 per patient 40. Beyond this, ITI
is not always successful, and even for those who see a reduction in antibody production there is
always a risk of inhibitor recurrence26.
Replacement therapy with porcine FVIII (pFVIII) is a second-line therapeutic for treating
those with inhibitors due to the low cross-reactivity between pFVIII and anti-human FVIII
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(hFVIII) antibodies42. In addition, pFVIII is a relevant FVIII replacement therapeutic in that it is
more stable and active than hFVIII due to a tighter binding interaction between the A2 domain
and activated pFVIII in comparison to hFVIII43. Novel human/porcine chimeric FVIII constructs
have been made to identify which domains contribute to the improvements seen in pFVIII
(Figure 7). The chimeric protein ET3i, which contains porcine A1 and A3 domains and human
A2, C1 and C2 domains has been shown to have better expression and activity levels than
hFVIII, both in vivo and in vitro expression systems. This was shown to be the result of a
reduction in the interaction with unfolded protein response chaperones in the endoplasmic
reticulum. Genetically
engineered protein
constructs such as ET3i are
promising therapeutics to be
able to mitigate the
inactivation of FVIII during
replacement therapy or in

Figure 7. Ribbon diagram
representation of ET3i
structure. Showing the three
human domains, hA2, hC1,
hC2 in salmon, purple, and
yellow, the two porcine
domains (pA3 and pA2)
shown in grey and raspberry.
Three metal ions are
embedded within the
trimeric A domain assembly:
Zn2+, Cu+, Ca2+ (PDBID#:
6MF0).
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potential gene therapy applications44.

FVIII Inhibitory Antibodies
Anti-FVIII antibodies are 150 kDa immunoglobulin G’s (IgG), the most common variety of
antibody found in circulation accounting for approximately 75% of all serum antibodies in
humans37. These glycoproteins fall within the immunoglobulin super family (IgSF) and are
comprised of a two heavy and two light chains. Each chain consists of a variable domain at its N
terminus and a constant domain at its C terminus, bound together via disulfide bonds (Figure
8). Within each of the variable domains lies three hypervariable complementarity determining
regions (CDR) which make up the antigen binding regions of the IgG, otherwise known as the
paratope. These paratopes specifically bind to a substrate, the antigen, at a targeted region, the
epitope65. IgGs are generated when a foreign protein within the bloodstream binds to B-cell
surface antigen-receptors. The foreign protein is then taken up into the B-cell where it is
degraded, and the generated fragments exposed to major histocompatibility II molecules.
Helper T cells then cause the B-cell to produce specific antibodies against the exposed peptide
fragments if these fragments are recognized as foreign46. The B-cell then produces clones,
which produce more antibodies with minor mutations, where the clones that produce the
highest affinity antibodies out-compete the others for survival. The B-cells that remain
following this process are known as memory B cells, which when activated produce clones that
secrete the given antibody. These cells are located within the spleen47. To produce FVIII
inhibitory antibodies within the laboratory, mice are treated with human FVIII via venous
injection to generate inhibitor producing B-cells. These B-cells are harvested from the mice and
used to generate B-cell hybridomas by fusing myeloma cancer cells with the spleen cells of
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inhibitor producing mice. These B-myeloma fusion cells serve to quickly divide allowing for
rapid growth and antibody expression.

Figure 8. Basic structure of Immunoglobulin G. Depicts the heavy chain in blue and the light
chain in green, with disulfide bridges labeled as S-S, and the Fab, Fc and antigen binding regions
denoted in the figure.

Anti-FVIII antibodies are classified dependent on their kinetics and extent of inhibition of
FVIII as either type I or type II inhibitors, and further classified based on their binding epitopes
as various groups. Type I inhibitors follow second-order kinetics (linear relationship between
inhibition and inhibitor concentration) and inactivate FVIII completely. Type II inhibitors have
complex kinetics (non-linear inhibition) and incompletely inactivate FVIII. Inhibitory antibodies
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primarily bind to the A2 and C2 domains of FVIII40. A2 inhibitors have been shown to inhibit
FVIIIa by preventing the Xase complex from activating FX, but still allow binding to FX 49. The
binding epitope for these anti-A2 antibodies is thought to be within residues 373-606, however
the details have yet to be defined structurally50. Anti-C2 antibodies are classified beyond types I
and II, with the sub-classifications classical and non-classical. Non-classical anti-C2 antibodies do
not disrupt phospholipid interactions, instead disrupting the activation of FVIII by interrupting
interaction with FXa or thrombin, while classical inhibitors disrupt phospholipid binding66.
Antibodies have been shown to also bind to the A3 and C1 domains with inhibitory action
against FVIII, however the A2 and C2 are the most immunogenic49.
Once bound to FVIII, inhibitors act to sterically block regions of FVIII resulting in loss of
function50. Contained within these epitopes are binding sites for several key binding partners of
FVIII including FIX, the phospholipid membrane of activated platelets, vWF, FXa and thrombin.
Inhibitors can target multiple epitopes and the target epitopes can change over time43. A
Bethesda assay is used to determine whether injected FVIII is functioning properly, or if a
patient’s immune system is neutralizing FVIII. Plasma from a patient undergoes a series of
dilutions, FVIII is added, and coagulation times are measured, with the results being given in
Bethesda units (BU). A BU is defined as the amount of inhibitor that eliminates half of FVIII
activity per mL of normal plasma, within two hours, incubated at 37 oC52. For reference, a high
responding inhibitor is defined as having more than five Bethesda units53.
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Antibodies of Study
Specifically, this study examines the anti-C1 human derived antibody NB2E9, and the
following anti-A2 murine derived antibodies: 4A4, 4F4, 1-D4, 2-101, and 4C7. NB2E9 is a type II
inhibitor in that it does not completely neutralize FVIII activity and has complex binding kinetics.
NB2E9 binds to the C1 and A3 domains of FVIII and was derived from a patient where the
antibody neutralized WT FVIII, but not the patients endogenous FVIII which contained a
mutation at Arg2150, placing importance on this residue for NB2E9’s binding epitope. NB2E9
acts to compete with vWF for binding to FVIII, which results in a time-dependent neutralization
of FVIII activity54. The five anti-A2 antibodies are also defined as being inhibitory or noninhibitory based on Bethesda assay and divided into either type I or type II dependent on the
degree of inhibition and binding kinetics. 4A4, 4F4 and 1-D4 are all type I inhibitory antibodies,
with 2-101 being a type II inhibitory antibody, and 4C7 being non-inhibitory. The A2 inhibitors
can be further classified into the following epitope groups: A, AB, BCD, C, D, DE and E based on
the pattern of overlap of their binding epitopes, as determined by ELISA. The various groups
indicate overlap in regions on the A2 domain where antibody binding occurs, and thereby
correspond to some level of commonality in their inhibition mechanisms. Most group A
antibodies bind to a previously determined epitope bound by Arg484-Ile508 in the N-terminal
region of A2, noncompetitively inhibiting binding to FIXa. Most group B and C antibodies show
little to no inhibition. Group D and E bind epitopes in the C-terminal of A2. Group E inhibits the
activation of FVIII by preventing thrombin from being able to cleave the FVIII light chain at
Arg1689. 4A4 is group A, 4F4 is group B, and 1-D4 and 4C7 are group E (Table 2)55.
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Table 2. Anti-A2 Antibodies
Monoclonal
BU/mg IgG
Antibody
4A4
40,000
4F4
330
1-D4
7,000
2-101
11,000
4C7
<1

Type

Group

I
I
I
II
Non-inhibitory

A
B
E
?
E

Binding
Epitope
Asp403-His444
Indeterminate
Glu604-Arg740
His444-Arg541
Indeterminate

While there is a seemingly never-ending variety of possible anti-FVIII inhibitory
antibodies which may develop in a patient, the most important aspect is the location of
inhibitory binding epitopes, and thereby the mechanism of inhibition. Neutralizing antibodies
prevent FVIII function by sterically blocking key interactions which are necessary for proper
FVIII functionality. Therefore, it is of significant interest in the ongoing development of
hemophilia A treatments to obtain structural data of FVIII’s interactions with inhibitory
antibodies. Doing so not only provides insight into the residues which play a role in the specific
inhibitory antibodies’ binding epitopes, but also a more comprehensive view of what residues
of FVIII are necessary for proper function, and therefore must remain spatially unhindered to
maintain this functionality. Notably, obtaining the first structures of FVIII in complex with antiA2 inhibitors and the C1 domain in complex with a human derived antibody will provide insight
into the inhibition mechanism of one of the two most immunogenic domains of FVIII as well as
confirm methods of inhibition generated with mouse derived antibodies via the C1 domain.
This information may provide valuable insight that would be crucial when designing
bioengineered FVIII therapeutics and in understanding the role of the A2 domain in terms of
FVIII function.
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Structural Investigations of FVIII-Antibody Complexes
Previous work to analyze the structure of FVIII in complex with inhibitory antibodies has
been done via x-ray crystallography as well as small angle x-ray scattering (SAXS)48, 49. X-ray
crystallography is dependent upon being able to crystalize your protein or proteins of interest.
Once crystals are obtained, they are exposed to x-rays, resulting in diffraction patterns that can
be utilized to gain information about the packing symmetry and size of the repeating crystalline
unit (protein) which can be used to gain knowledge of a protein’s structure56. The limiting step
within this process is the formation of a high enough quality protein crystal to obtain diffraction
data. This is typically done via hanging drop vapor diffusion. Not only do you have to obtain
high enough concentrations of sample and find the proper environmental conditions to cause
protein crystallization, but you must also wait for a crystal to form which can take anywhere
from 10 minutes to a year51. This has been successful when working with FVIII in complex with
inhibitory antibodies in the past, but difficulty in complex production and crystallization varies
for any given complex58. Alternatively, SAXS has also been employed to examine the structures
of FVIII complexes. Unlike x-ray crystallography, SAXS does not require the crystallization of
protein. Instead of examining the diffraction pattern of a protein crystal, SAXS relies on the
elastic scattering behavior that x-rays display when traveling through a material and analyzing
the resulting scattering angles. This is accomplished by shining x-rays through a liquid sample
and recording these scattering angles59. Furthermore, SAXS, unlike crystallography, allows for
the investigation of conformational shifts with a protein without needing to generate structures
from different samples. However, this is a result of spatial averaging that is employed when
analyzing data, which leads to loss of resolution in comparison to crystallography and SAXS is
22

often described as being a low-resolution technique (does not give information on atomic
coordinates, instead giving an envelope of more generalized density)60. In preparing samples for
use in SAXS or x-ray crystallography, one must obtain samples of known concentrations that are
highly pure and identical, free of contaminates or aggregation, in a known buffer. Failing to do
this leads to unusable data67. Gleaning structural information about the binding epitopes of
anti-FVIII antibodies, in conjunction with their method of FVIII inhibition provides invaluable
insight into the mechanics of FVIII’s function, as observed in the development of the C2 domain
phospholipid binding model.

Phospholipid Binding Model
The lipid binding model of FVIII has been developed and built upon since the first crystal
structure of the FVIII C2 domain, published in 1999, revealed the presence of two hydrophobic
beta-hairpin loops within the C2 domain that extend beyond the globular fold of the protein.
These loops, which are surrounded by basic residues, were proposed to extend into the
anhydrous interior of the phospholipid bilayer68. Since then, detailed structural investigations of
the FVIII C2 domain both alone and in complex with antibodies, have continued to refine the
binding model. Multiple studies have shown the two solvent-exposed hydrophobic loops to
associate with the anhydrous interior of lipid bilayers (L2251/L2252 and M2199/F2200)68,69. In
conjunction with this hydrophobic interaction is a ring of positively charged, basic residues
adjacent to the solvent-exposed loops, that are thought to interact with the negatively charged
phosphatidylserine (PS) on the surface of activated platelets69. This model of lipid binding via
these hydrophobic loops is further supported by a structure of the C2 domain in complex with
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human-derived classical inhibitory antibody B02C11. The CDR loops of B02C11’s variable region
completely segregate the hydrophobic loops of C2, resulting in a loss of lipid binding70. While all
signs point that FVIII’s binding interaction with phospholipids is driven by the hydrophobic
solvent exposed loops of the C domains embedding into the lipid bilayer, the orientation of the
protein during lipid binding is a bit more elusive.
The FVIII lipid binding model has been further elaborated upon thanks to epitope
mapping via the crystal structure of isolated C2 ternary complex with two pathogenic
antibodies, G99 and 3E6. 3E6 is a classical inhibitor (prevents lipid binding) while G99 is a nonclassical inhibitor (allows lipid binding). By examining the locations of the two different, nonoverlapping epitopes of these antibodies (one inhibitory to lipid binding the other having little
to no effect on lipid binding) one can make extrapolations about whether these areas of the C2
domain are, or are not, involved in lipid binding. This ternary structure of C2 provided valuable
insight into the orientation of the binding interactions, drawing importance away from residues
previously thought to be involved in lipid binding that were found to be within the G99 epitope.
In addition, the 3E6 epitope did not include the two hydrophobic loops, however, it illustrates
complete loss of lipid binding by instead sequestering basic residues adjacent to these loops.
This suggests that lipid binding is driven by both hydrophobic and electrostatic interactions in
conjunction with one another, as opposed to the electrostatics providing a supporting role to
the hydrophobic loops. By overlaying high resolution structures of C2 in complex with B02C11,
3E6 and G99 a lipid binding model was built, with the hydrophobic loops bound to B02C11
within the anhydrous lipid membrane, positively charged basic residues bound to 3E6 in an
orientation that allows them to interact with the negatively charged surface of activated
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platelet membranes and the residues bound to G99 facing away from the lipid membrane
(Figure 9)71.

Figure 9. Inhibitor based platelet binding model of FVIII C2 domain (shown in purple). A) Anti-C2
inhibitors in complex with isolated FVIII C2 domain, alignment of classical inhibitors 3E6, yellow,
and B02C11, cyan, with non-classical inhibitory G99, green (PDB #4KI5 and #1IQD). B)
Hydrophobic residues make up two loops which insert the anhydrous leaflet of platelet
membranes and make up the binding epitope of B02C11 shown in cyan. Basic residues interact
with the negatively charged headgroups of PS made up of the binding epitope of 3E6, shown in
yellow, while the binding epitope on the non-classical antibody G99 faces away from the lipid
membrane interface, shown in green76. Key residues for 3E6 and B02C11 binding are shown as
sticks and labeled. (PDB #6MF0).

Phospholipid C Domain Electrostatic Interactions
When activated, there is a recruitment of PS to the surface of platelet membranes,
resulting in a negative shift in the charge on the membrane surface. Without this negative
charge, FVIII has little to no affinity to phospholipids72. Studies have shown that FVIII specifically
binds to the L-isomer of PS (OPLS), while >95% of FVIII activity is lost when the D-isomer is used
(OPDS)73. Similarly, studies have found that the C2 domain on its own lacks this specificity
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(maintains specificity for negatively charged lipids), while a C2-deleted FVIII construct, retained
its specificity of OPLS binding. Beyond this, C2 was shown to have a loss of lipid binding in the
presence of physiological concentration of NaCl, while full length FVIII saw a 2-fold decrease in
binding affinity while retaining some binding, reflective of a loss of the C2 domain’s binding
affinity64. Examining homology modeling alongside membrane binding predictions implicate
two arginine residues of the C1 and C2 domains in phospholipid binding, R2320 of the C2 and
R2163 of the C174. Examining C2 mutational data, the R2320T hemophilia A mutation has been
shown to have only 5% activity relative to WT and is conserved across species as well as the
homologous C domains of FV and Lactadherin, in addition to the FVIII C1 domain75. Electrostatic
surface mapping illustrates that the R2320 residue has the greatest basic electrostatic potential
of the C2 domain, suggesting the importance of this residue in stabilizing interactions with
negatively charged phospholipids. Unfortunately, there is little mutational or assay-based data
examining the C1 domain, and as such few inferences can be made about the R2163 residue.
However, this residue is conserved across species and between homologous proteins.
Unpublished mutational data from the Spiegel lab has shown a near complete loss of C1C2 lipid
binding when the R2163 and R2320 residues are mutated to serine, validating the importance
of these residues in this key interaction.
All of this implies that the binding interactions of the C2 domains hydrophobic loops acts
in conjunction with electrostatic interactions between the protein and the lipid. Additionally,
this indicates that the C2 domain acts in cooperation with other domains to be specifically
recruited to the surface of activated platelets. While this alongside the apparent flexibility of
the C2 domain and loss of lipid affinity in the presence of physiological NaCl concentrations
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appears to imply that a different region of the protein (likely C1) acts to initially recruit and bind
FVIIIa, followed by conformational shifts in the C2 domain to stabilize lipid binding and
eventually allow for FVIIIa dissociation, the exact mechanism of lipid association and
dissociation has yet to be fully understood.
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Research Aims
Furthering our understanding of both the mechanism of function and mechanism of
inhibition of FVIII and the key residues therein provides a blueprint when designing hemophilia
A therapeutics. The goals of this study included the successful optimization of five anti-A2
inhibitor Fab fragments, the successful crystallization and collection of diffraction data for the
4A4 Fab, as well as the formation of inhibitor:ET3i complexes for use in structural study. SAXS
data was successfully collected for six different inhibitor-ET3i pairings, providing insight into the
binding epitopes and possible mechanisms of inhibition of anti-A2 inhibitors 4F4 and 4A4.
Additional strides were made in obtaining x-ray diffraction data for the 4A4:ET3i and human
derived NB2E9:C1 complexes. Beyond this, progress was made in the confirmation of proposed
docking and undocking conformations of the C2 domain, by designing mutants that would lock
the C1C2 construct in its undocking conformation. Four various ‘disulfide’ mutants were
successfully purified with one of these mutants being shown to have successfully formed an
additional disulfide bond when compared to the WT. Efforts are currently ongoing on both of
these fronts.
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Materials and Methods
Determination of C1C2 Cysteine Mutation Sites
Potential residues for cysteine mutations were identified using FVIII structural models in
PyMol, PDB ID 6MF0 and 7K66. Residue pairs were chosen based on the distances between
their alpha carbons in the proposed docking conformation vs. the proposed undocking
confirmation of the C2 domain of FVIII. Four residue pairs were chosen that were modeled to
be close enough to form a disulfide bond in the undocking confirmation, while being far enough
apart in the docking confirmation to be unable to form a disulfide linkage with the hope of
locking the mutant C1C2 construct in the undocking confirmation.

Transformation of FVIII C1 and C1C2 Domain Containing Plasmids
hFVIII C1C2 domain (residues 2087-2350) were ordered from Genscript in a pET32a+
vector using BamH1 and Xho1 restriction sites. FVIII C1C2 residues were transformed into
chemically competent C3029J Shuffle K12 E. coli cells following New England Biolabs’ high
efficiency transformation protocol with the following mutations: H2031C/V2294C,
T2023C/S2175C, T2023C/V2294C, T2023C/L2324C. Transformed cells were plated on agar
plates containing 100 μg/mL ampicillin and grown at 30 oC for 24 hours. Single colonies were
harvested from the ampicillin plates and allowed to grow in LB at 30 oC, 180 RPM for 16-18
hours. Following this growth phase cell cultures were stored at -80 oC, 20% (v/v) glycerol.
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Growth, Expression, and Purification of C1 WT and Mutant C1 Constructs
Overnight cultures were grown from E. coli Shuffle K12 cells stocks in 10 mL LB, at 30 oC
while shaking at 180 RPM and added to 1 L of 2xYT media with 40 mM MgCl 2 and 40 mM KCl,
while maintaining 30 oC and 180 RPM until the 600 nm absorbance reached 0.6-0.8. Once the
proper absorbance values were reached the temperature was adjusted to 15 oC and 200 RPM
and the flasks were allowed to cool for 30 min, following which protein expression was induced
via the addition of isopropyl B-D-thiogalactopyranoside (IPTG) to 500 µM and left overnight for
18-20 hours. Cells were pelleted by centrifugation at 6371x g for 10 min at 4 oC (FIBERLite F106x500y rotor, Thermo Fisher Scientific). Pellets were divided into 50 mL falcon tubes with pellet
from 3 L of cell growth per tube and resuspended in 30-35 mL of cold Lysis buffer (300 mM
NaCl, 20 mM Tris-HCl pH 7.5, 10 mM imidazole pH 8.0, 10.0% (v/v) glycerol and 0.5% (v/v)
Triton X-100) 350 µL of 100 mM phenylmethylsulfonyl fluoride (PMSF) was added followed by
700 µL of 50 mg/mL lysozyme. The resuspended cell slurry was then allowed to enzymatically
lysed while rotating at 15-20 RPM for 30 min at 4 oC, following which the cells were
mechanically lysed using a Branson Sonifier 450 probe at power output 5 and duty cycle 50%
for 30 seconds three times with a 30 second rest between each cycle. Cell debris was removed
via centrifugation at 16,500 RPM for 45 min at 4 oC (FIBERLite F21- 8x50y rotor, Thermo Fisher
Scientific), followed by filtration with 5 µm sterile syringe filters. Immobilized metal affinity
chromatography (IMAC) was performed using TALON cobalt immobilized affinity resin (TAKARA
Bio) which was equilibrated in lysis buffer, using 1 mL settled resin per 2 L cell growth. Resin
was incubated with filtered lysate for 15 min rotating at 15-20 RPM at 4 oC. Resin was then resettled in column and rinsed with 15 CV of lysis buffer, 30 CV ATP wash buffer (10 mM ATP, 50
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mM HEPES pH 7.4, 300 mM KCl, 10 mM MgCl2) with a pause after the first 15 CV ATP wash
where the resin was resuspended on column and allowed to resettle for 10 min before finishing
the wash step, 30 CV lysis buffer, 30 CV wash buffer (20 mM HEPES pH 7.4, 300 mM NaCl, 15
mM imidazole, 10% v/v glycerol), and eluted with elution buffer (20 mM MES pH 6, 300 mM
NaCl, 150 mM imidazole, 10% v/v glycerol) after allowing the elution buffer to incubate on
column for 10 min. Eluted protein was concentrated and dialyzed into storage buffer consisting
of 20 mM HEPES, 300 mM NaCl, 10% v/v glycerol, pH 7.4-8.0 and subsequently concentrated
with a 10 kDa spin filter to a concentration between 0.2-1 mg/mL and stored at -80 oC. Purity
was accessed via SDS-PAGE using 12.5% bis-acrylamide gels.

Growth, Expression, and Purification of C1C2 WT and Mutant C1C2 Constructs
Overnight cultures were grown from E. coli Shuffle K12 cells stocks in 10 mL LB, at 30 oC
while shaking at 180 RPM and added to 1 L of 2xYT with 40 mM MgCl 2 and 40 mM KCl, while
maintaining 30 oC and 180 RPM until an OD600 of 0.4-0.6. Once the proper absorbance values
were reached the temperature was adjusted to 15 oC and 200 RPM and the flasks were allowed
to cool for ~30 min, following which protein expression was induced via the addition of
isopropyl B-D-thiogalactopyranoside (IPTG) to 500 µM and left overnight for 18-20 hours.
Pellets were divided into 50 mL falcon tubes with pellet from 3 L of cell growth per tube and
resuspended in 30-35 mL of cold Lysis buffer 350 µL of 100 mM PMSF was added followed by
700 µL of 50 mg/mL lysozyme. The resuspended cell slurry was then allowed to enzymatically
lysed while rotating at 15-20 RPM for 30 min at 4 oC, following which the cells were
mechanically lysed using a Branson Sonifier 450 probe at power output 5 and duty cycle 50%
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for 30 seconds three times with a 30 second rest between each cycle. Cell debris was removed
via centrifugation at 16,500 RPM for 45 min at 4 oC (FIBERLite F21- 8x50y rotor, Thermo Fisher
Scientific), followed by filtration with 5 µm sterile syringe filters.
The filtered sample was then loaded onto a Capto HisTrap HP 5 mL column attached to a
fast protein liquid chromatography (FPLC) device (AKTA prime Plus manufactured by GE
Healthcare Life Sciences) equilibrated in lysis buffer at 2 mL/min. The column then underwent
several wash steps all at a flow rate of 3 mL/min. First, buffer A (500 mM NaCl, 20 mM
imidazole, 50 mM HEPES, pH 7.4) until the UV and conductance baselined, ~50 mL. Next the
column was washed with 50 mL of freshly prepared ATP wash buffer (300 mM KCl, 50 mM
HEPES pH 7.4, 20 mM MgCl2, 10 mM ATP) flow was stopped for 10 minutes following which an
additional 50 mL of ATP wash buffer was flown over the column. Flow was then switched back
to buffer A and ran until the UV and conductance baselined, ~70 mL. Flow was then switched to
92% buffer A, 8% buffer B (500 mM NaCl, 500mM imidazole, 50 mM HEPES pH 7.4) and ran
until UV and conductance baselined. Finally, a gradient elution was conducted over the course
of 100 mL going from 8-100% buffer B and collected in 4 mL fractions. Each fraction was
collected, and purity determined via SDS-PAGE. Fractions with >95% purity were dialyzed into
storage buffer consisting of 20 mM HEPES, 500 mM NaCl, 10% v/v glycerol, pH 7.4-8.0 and
stored at -80 °C.

TEV Cleavage
Plasmids ordered from Genscript contained a tobacco Etch Virus (TEV) cleavage
sequence between the C1 or C1C2 domains and a penta-His tag and Thioredoxin solubility tag.
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Cleavage reactions were conducted by adding 25 µL of 1 mg/mL TEV per 2 mg of protein with
the reactions being conducted at 30 °C 150 RPM for ~3.5 hours. Following which, the sample
was collected, and the cleaved C domains were purified via IMAC using ~1-2 mL Talon resin. The
sample was incubated with the talon resin for ~30 minutes and the flow through was collected,
purity accessed via SDS-PAGE and the sample stored at -80 °C.
The C1C2 H2031C/V2294C was additionally purified on size exclusion chromatography
(SEC) (S75, Cytiva Life Sciences) equilibrated in HBS with 450 mM NaCl. The fractions were
accessed for purity via SDS-PAGE and pure fractions were pooled.

Mass Spectrometry
Molecular weights of WT and mutant C1C2 constructs were verified following an LC-ESIMS workflow using an Agilent 6545XT AdvanceBio Q-TOF system in conjunction with an Agilent
1290 HPLC system. Prior to use, a mass calibration check was conducted with masses ranging
from 118.08 to 2721.89 Da. Prior to loading samples, the system was conditioned with buffer A
(H2O 0.1% formic acid) at a flow rate of 0.3 mL/min, following which a full gradient elution was
conducted with no sample injection as follows; 0.0-1.0 min 90% buffer A 10% buffer B (100%
MeCN), 1.0-9.0 min linear gradient of 10-90% buffer B, 9.0-11.0 min 90% buffer B, 11.0-11.1
min linear gradient of 90-10% buffer B, 11.1-15.0 min 10% buffer B, all while collecting MS data.
Following this ‘no injection’ sample was injected into the HPLC and the same gradient elution
procedure was followed for each subsequent sample. Once loaded onto the system samples
were first desalted and then separated via the gradient elution using a Phenomenex Aeris 3.6
mM WIDEPORE C4 200 Å column (100x2.1 mm). After all samples were run a second ‘no
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injection’ sample was conducted. Peptides were ionized via electrospray ionization (ESI) and
loaded onto the Q-TOF. The ESI source was set as follows; gas temp 350 °C, drying gas 9 l/min,
nebulizer 35 psi, sheath gas temp 325 °C, sheath gas flow 8 l/min, VCap 4500 V, fragmentor 225
V, skimmer 70 V. Ion charge ladders were deconvoluted using Agilent MassHunter BioConfirm
software (ver. 10.0) with a mass range of 30,000-60,000 Da.
In addition to running unmodified samples, various modified samples were also run over
the same LC-ESI-MS workflow, while following the same gradient elution and data work-up
procedure. Both WT C1C2 and each of the disulfide mutants were subjected to the following
modifications and run on the MS: reduced with dithiothreitol (DTT), reduced with DTT then
alkylated with iodoacetamide (IAA). Additionally, a reducing fine screen was conducted by
treating the H2031C/V2294C mutant with a range of DTT concentrations; 0.05 mM to 5 mM.

Mammalian Cell Growth
In a sterile hood, 9 mL of Hybridoma Medium E (MedE) from STEM Cell Technologies
(CAT#03805) was placed into a sterile 15 mL falcon tube. Hybridoma cell stocks stored in liquid
nitrogen at ~1 million cells/mL in CryoStor® CS10 from STEM Cell Technologies (CAT#07959)
were thawed in a 37 oC water bath for 2 min. Thawed cell stocks were added to the 9mL MedE
aliquot, and gently inverted to mix. Cells were pelleted by centrifugation at 1000 RPM for 5
min. The supernatant was discarded and the hybridoma cells gently resuspended in 2 mL of
MedE, this 2 mL suspension was transferred to a T-75 flask containing 15-25 mL of MedE. The
flask was loosely sealed and stored in a sterile water bath incubator at 5% CO 2 and 37 oC. Cells
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were monitored over a 10-day growth period considering cell adherence to the flask, percent
confluence and color of media. Once cells reached 50% or higher confluence the MedE was
disposed of and 5 mL of Animal Origin Free (AOF) media from STEM Cell Technologies
(CAT#03835) was added to the flask. Cells were sloughed off the flask by gently slapping and
scraping the inside of the flask with a sterile serological pipet. Cell density and viability were
assessed by combining 200 µL of Trypan Blue solution (0.4%) (CAT#T8154) with 50 µL of
sloughed cell media and placing 20 µL of this mixture onto an INCYTO C-Chip hemocytometer
(DHC-N01), counting the number of viable cells within a 1 mm2 grid, and extrapolating the cell
count for the cell slurry. The remaining AOF cell slurry was then collected, and the cells
passaged into new T-75 flasks containing 15-25 mL of AOF or MedE at a rate of ~1 million cells
per MedE flask and ~2 million cells per AOF flask. Following passaging, the original MedE flask
would either be discarded or recycled by adding an additional 15-25 mL of MedE and allowing
the remaining adherent cells to repeat the 10-day growth period.

Antibody Collection from AOF Media
While the hybridoma cells express anti-fVIII antibodies throughout the growth process,
the collection of these antibodies was done in AOF media. Following passaging into AOF
containing T-75 flasks, the cells were left to grow and express for ~10 days. Following this
expression period, the media was harvested and spun at 1000 rpm for 5 minutes at room
temperature, the supernatant collected, and 20% sodium azide added to the supernatant to a
final concentration of 0.1%. This antibody containing media was stored for under 5 days at 4 °C
or at -80 °C for long term storage.
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Antibody Purification with Protein A Resin
The collected antibody containing media was diluted at a ratio of 1:1 with antibody
binding/wash buffer (0.1 M HEPES, 0.15 M NaCl pH 8). The diluted media was run over 2-3 mL
of Protein A resin in a disposable gravity column at a flow rate of 1 mL/min or less, and the FT
collected. The column was then washed with 5 CV of antibody binding/wash buffer and the
wash collected. Elution was conducted with 15 mL of 0.2 M glycine pH 2.0-3.0 and collected
into a falcon tube containing 1.5 mL of 1.5 M Tris-HCl pH 8.8 and 1.5 mL of 5 M NaCl. Purity was
accessed via SDS-PAGE, and stored at -80 °C.

Antibody Cleavage with Immobilized Papain
The antibody sample was buffer exchanged into sample buffer (10 mM EDTA, 20 mM Na
phosphate, pH 7) and ~150 μL of immobilized papain slurry (CAT#20341) equilibrated in
digestion buffer (10 mM EDTA, 20 mM NaP, 20 mM cysteine-HCl, pH 7) was added per mg of
antibody, with the digestion buffer being prepared immediately prior to use. The cleavage
reaction was conducted overnight in a shaking water bath at 37 °C and 180 RPM. Following
cleavage, the papain resin was removed from the sample, and the sample was diluted with
~1/5th the sample volume PBS. ~300 μL of protein A slurry (CAT#20333) equilibrated in PBS was
added to the sample and placed on a rocker for 1-2 hours. Following incubation with protein A
the protein A resin was removed from the sample and Fab purity and cleavage success was
accessed via SDS-PAGE. The Fab sample was dialyzed into PBS and stored at -80 °C.
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Antibody-FVIII Complex Formation
Two ‘types’ of antibody-FVIII complexes were formed; full length ET3i, obtained from
our collaborators Dr. Christopher Doering and Dr. Gabriela Denning, in complex with one or two
murine derived anti-FVIII Fab in complex with full length ET3i, and human derived anti-C1
NB2E9 Fab, obtained as an monoclonal antibody (mAb) from our collaborators Dr. Carmen
Coxon, with cleaved WT FVIII C1 domain. When forming the anti-A2-ET3i complexes both the
Fabs and ET3i were buffer exchanged into 1x HBS with 5% v/v glycerol. These proteins were
mixed at a molar ratio of 1:1.2 ET3i:Fab or 1:1.2:1.2 ET3i:Fab:Fab and let sit on ice for ~30 min.
The complexes were then spun in a 10 kDa spin filter to concentrations between 1-2 mg/mL
and stored at -80 °C. When forming the NB2E9-C1 complex the proteins were buffer exchanged
into 1x HBS with 5% v/v glycerol. These proteins were mixed at a ratio of 1:2 Fab:C1 and let sit
on ice for ~30 min. The complex was then spun in a 30 kDa spin filter to a concentration of 1.2
mg/mL and stored at -80 °C.

Antibody Complex SEC
Anti-A2-ET3i complexes used for small-angle X-ray scattering (SAXS) were purified via
SEC (S200, GE Healthcare) equilibrated in HBS. Peaks were collected and purity tested by SDSPAGE gel, the complex and excess Fab were collected separately and stored at -80 °C.

Small Angle X-Ray Scattering
The following binary and tertiary ET3i-antibody complexes, purified via SEC, were sent
to the Advanced Light Source (ALS) Berkeley Center for Structural Biology (BCSB) Sibyls
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Beamline 12.3.1 (Berkeley, Ca) and SAXS data collected for each ; 1-D4:ET3i, 1-D4:G99:ET3i, 2101:ET3i, 2-101:G99:ET3i, 4F4:ET3i, 4F4:G99:ET3i, 4A4:ET3i, 4A4:G99:ET3i, 4C7:ET3i,
4C7:G99:ET3i. This work was conducted at the ALS, a national user facility operated by
Lawrence Berkeley National Laboratory on behalf of the Department of Energy, Office of Basic
Energy Sciences, through the Integrated Diffraction Analysis Technologies (IDAT) program,
supported by DOE Office of Biological and Environmental Research. Additional support comes
from the National Institute of Health project ALS-ENABLE (P30 GM124169) and a High-End
Instrumentation Grant S10OD018483.

Crystallography
The NB2E9 Fab-ET3i complex was sent to the Hauptman-Woodward Medical Research
Institute National High-Throughput Crystallization Center (HWI) for hanging drop crystal
screening of 1,536 different chemical conditions. The crystallization screening at the National
Crystallization Center at HWI was supported through NIH grant R24GM141256. A variety of
fine screens were designed and plated based on the HWI screen. These fine screens yielded
crystals, which were looped and sent to the ALS BCSB beamline 5.0.1 (Berkeley, Ca), however
none of these crystals diffracted.
The NB2E9:C1 complex was then sent to HWI for hanging drop crystal screening of 1,536
various chemical conditions. The crystallization screening at the National Crystallization Center
at HWI was supported through NIH grant R24GM141256. From this a variety of fine screens
were designed and plated. These fine screens have yielded crystals, some of which have been

38

looped and sent to the ALS BCSB beamline 5.0.1, however none of these crystals showed
diffraction.
The 4A4, 4F4, and 4C7 FabS were screened in house using the following screens from
Hampton Research; PEG/Ion Screen™ (HR2-126), PEGRx 2 Screen™ (HR2-084), Crystal Screen
HT™ (HR2-110). A variety of fine screens were designed and plated, based on the initial
screening, which yielded crystals that were looped and sent to the ALS BCSB beamline 5.0.1.
A lone 4A4 crystal grown via hanging drop vapor diffusion in 0.2 M calcium chloride dihydrate
and 20% PEG 3350 and cryoprotected with a 1:1 addition of 0.2 M calcium chloride dihydrate,
and 40% PEG 3350, yielded usable diffraction data. Crystal growth occurred over the course of
approximately one week at room temperature. Based on the successful crystallization and
diffraction of the 4A4 Fab, the 4A4:ET3i complex was constructed and sent to HWI for hanging
drop crystal screening of 1,536 different chemical conditions. A variety of fine screens were
designed and plated based on the HWI screen.

Nanodisc Preparation
MSP1D1 grown and purified by previous students was cleaved with TEV by adding 25 μL
of 1 mg/mL TEV per 2 mg of MSP1D1 and allowed to react for ~3.5 hours at 30 °C 150 RPM. 1,2dioleoyl-sn-glycero-3-phosphocholine (DOPC) and 1,2-dioleoyl-sn-glycero-3-phospho-L-serine
(DOPS), stored in chloroform were mixed in a glass tube at a molar ratio of 80:20, and the
chloroform dried overnight in a fume hood. Lipids were solubilized with 100 μL 1x HBS
containing 26 mM sodium chocolate. Lipids were solubilized by hot running tap water (~40-50
°C), vortexing, and water bath sonication until the lipid solution turned clear. MSP1D1 were
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added to a final molar ratio of 1:200 MSP:lipid, additional sodium cholate was added to a final
concentration of 50 mM and additionally HBS was added to a final volume of 500 μL. This
mixture was incubated for one hour at 37 °C, following which 500 μL of Biobeads equilibrated in
HBS were added and the mixture sat overnight, mixing, at 4 °C. Samples were purified via size
exclusion chromatography (S200, GE Healthcare) equilibrated in HBS. Peaks were collected and
nanodiscs were tested by assessing binding to WT C1C2 via biolayer interferometry (BLI).
Fractions were pooled based on C1C2 binding curves, and stored at 4 °C.

Biolayer Interferometry
Biolayer interferometry (BLI) was used to confirm binding between antibody-protein
and protein-lipid interactions. BLI was conducted with a Pall ForteBio® BLITz instrument
alongside the BLITz Pro software. BLI was conducted in five different steps: initial baseline,
loading, baseline, association, dissociation. First, a BLI tip was attached to the instrument and
200 μL of HBS were added to a LiteSafe® Black Microtube, the BLI run was then started, and the
tip submerged in the black microtube for the initial baseline. Following this the tip is moved
into 4 μL of sample (with affinity for the tip in question) for the loading step, following this the
tip was resubmerged in the black microtube for the baseline step. The tip, bound to the target
protein, was then placed into 4 μL of the second sample and the two samples were allowed to
interact for the association step, following which the tip was placed back into the black
microtube for the dissociation step. In addition to testing samples a negative control was
measured during each BLI run, which follows the same procedure as a regular BLI run, except
instead of placing the tip into the sample with affinity for the tip during the loading step the tip
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was placed in 4 μL of HBS.
Two different tips were used when conducting BLI: Octet® HIS1K Biosensors and Octet®
ProA Biosensors. The HS1K Biosensors were used to bind to C1, C2, and C1C2 constructs to
assess binding with lipid vesicles and lipid nanodisc, the ProA Biosensors were used to bind to
IgG to assess binding with Et3i, C1, C2, and C1C2 constructs.

Results
FVIII Mutant Design
ET3i structures of the proposed docking and undocking conformations were used to
identify residues to mutate to cysteine. Residues were chosen such that the distance between
the alpha carbons was close enough to form a disulfide linkage in the ‘undocking’ conformation
while being too far apart in the ‘docking’ conformation. Disulfide bonds can form when the
alpha carbons of two cysteines are within ~8 Å 77. As such, the parameters for picking residues
were that in the undocking conformation the two residues’ alpha carbons were within ~8 Å
with an increase in distance between alpha carbons in the docking conformation. Four residue
pairs were identified and ordered (Figure 10).
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Figure 10. C1C2 disulfide mutant design. A) C1C2 in the proposed undocking conformation, C1
in orange, C2 in green, the residues of interest are colored in purple and labeled, the two native
disulfide bonds of C1C2 are shown in yellow. B) Mutation residue pairs showing the distance
between alpha carbons in the proposed undocking, C1 orange and C2 green, and proposed
docking, C1 cyan C2 purple, conformations. Nitrogen is shown in blue, and oxygen shown in
red. Residues and bond distances are labeled. (PDB# 6MF0).
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FVIII C domain expression and purification
Wild type hC1C2, hC1 and their various mutants were successfully transformed into
SHuffle K12 E. coli cells to assist in proper disulfide bond formation. The SHuffle K12 cell line
yielded successful expression of soluble WT C1C2, C1 as well as the various mutants. Following
IMAC, samples consistently contained a 70 kDa contaminant that was able to be removed on a
protein-by-protein basis. The WT C1 and C1C2 were able to be purified with a typical IMAC
purification scheme with the addition of ATP washes to remove the contaminant (Figure 11),
with yields of approximately 4 mg/L and 1 mg/L pure protein, respectively (Table 3). This
proved to be unsuccessful when purifying C1 and C1C2 mutants. C1C2 mutants
(R2163S/R2320S, T2023C/V2294C, T2023C/L2324C, T2023C, S2175C, H2031C/V2294C) and the
C1 mutant (R2163S) were able to be purified with a gradient elution on FPLC using a nickel
affinity column with large imidazole and ATP wash steps (Figure 11). Notably, the same
purification protocol was successful in purifying all the various mutants. Mutants
R2163S/R2320S and R2163S were both used in lipid binding studies as described by Peters,
202183.
Table 3. Approximate C1 and C1C2 Construct Expression Levels and Purification Scheme
Protein

Average Yield of Pure Protein

Purification Scheme

WT C1

4 mg/L

IMAC, additional clean-up as needed

WT C1C2

1 mg/L

IMAC, additional clean-up as needed

C1 Mutant

~0.9 mg/L

FPLC Ni column, or successive IMAC

C1C2 Mutants

~0.333 mg/L

FPLC Ni column
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Figure 11. C1 WT initial purification, cleavage, and subsequent purification. A) SDS-PAGE gel
image of a typical C1 Talon IMAC purification, and post TEV cleavage sample. All the different
lanes are labeled, with un-cleaved C1 boxed in yellow, and cleaved C1 boxed in green. B) SDSPAGE gel image of cleaved C1 on a Q-column, lanes are labeled and cleaved C1 is boxed in
green. C) Q-column chromatogram, each of the different purification steps are labeled, with
pure cleaved C1 denoted with a green star.
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Figure 12. C1C2 disulfide mutant purification. A) SDS-PAGE gel image of C1C2 T2023C, S2175C
FPLC Ni-NTA purification, with fraction number X labeled as f. X. Non-pure samples are boxed in
red and pure samples are boxed in yellow, corresponding to the red and yellow stars on the
chromatograph. B) Ni-NTA chromatogram of C1C2 T2023C, S2175C purification, absorbance
shown by the blue curve, and % buffer B shown by the orange curve. The black star shows the
end of the ATP wash and the elution of the 70 kDa contaminant, the red star shows the
beginning of elution off the column, matching the fractions boxed in red on the gel image, and
the yellow star shows the elution of the purified sample, corresponding to the yellow boxed
fractions on the gel image. See appendix figures 2-4 for purification of the other three disulfide
mutants.
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C1 WT TEV Cleavage
Recombinant WT C1 contained a TEV cleavage site as previous attempts to cleave the
protein ran into difficulties when using enterokinase. TEV cleavage was optimized such that
cleavages occurred over the course of ~3 hours at 37 C. Minimal protein precipitation was
c

observed when compared to overnight cleavages at 4 C. Purification of the cleaved C1 was
c

successful in removing all contaminants, either through IMAC purification or IEC. Using talon
resin the cleaved HIS-TRX tag and HIS-TEV were bound to the column as the untagged C1
flowed through. This, however, would not always be enough to purify the sample, in which case
purification using a Q column was conducted at a pH of ~7. C1 has a basic theoretical pI of 9.96,
and so at a pH of around 7 it would have a positive charge removing affinity for the column. On
the other hand, both TEV and TRX have theoretical pIs of less than 6 giving them a negative
charge at this pH and a high affinity for the column.

Disulfide Mutants
During the COVID pandemic there were numerous supply chain issues, including ATP, so
while the C1C2 mutants T2023C/V2294C, T2023C/L2324C, T2023C, S2175C, H2031C/V2294C
(disulfide mutants) were able to be successfully purified on FPLC with an ATP wash, alternative
methods were attempted. These all proved to be unsuccessful in purifying the target protein to
the same degree as the ATP method, and so “PEAK ATP®”, a work-out supplement advertised
as “Pure ATP” was bought from amazon and used in lieu of laboratory grade ATP. This ATP
replacement showed excellent promise and was able to remove the 70 kDa contaminant to a
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comparable degree on IMAC wash steps, however it was not fully pursued as laboratory grade
ATP became available.
The identity of the disulfide mutants was validated and the constructs assessed for
proper folding via binding kinetics to anti-C1 and anti-C2 inhibitors via BLI. The molecular
weight of the formed constructs were further validated via mass spectrometry (MS). This
proved to be successful in confirming the MW of 3 of the 4 disulfide mutants as well as WT
(Table 4).
To test if the desired disulfide bond had formed, MS data was collected for both
reduced and non-reduced samples of the disulfide mutants. As the formation of a disulfide
bond reduces the molecular weight of a protein by 2 Da78, the number of disulfide bonds within
a protein can be determined by comparing the weights of reduced and non-reduced samples.
This successfully illustrated the formation of a new disulfide bond for C1C2 mutant
H2031C/V2294C, via an 8 Da shift between the reduced and non-reduced samples (Figure
13). The H2031C/V2294C was then further purified on SEC in preparation for conducting lipid
binding assays (Figure 14). Initial reducing and alkylating conditions were tested for the
H2031C/V2294C mutant. Reduction was successful, however the expected molecular weight
shift that would be seen via successful alkylation with IAA was not observed.
Table 4. C1C2 Disulfide Mutant’s Molecular Weights
Mutant
Theoretical Molecular
Weight (kDa)
T2023C/V2294C
54.446
T2023C/L2324C
T2023C, S2175C
H2031C/V2294C
WT

54.432
54.458
54.410
54.440
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Molecular Weight Found on
MS (kDa)
54.3-54.5
N/A
54.366
54.280
53.307

Figure 13. Mass chromatogram for C1C2 H2031C/V2294C under reducing and non-reducing
conditions. A) Reduced sample, showing a mass of 54,280 Da B) Non-reduced sample, showing
a mass of 54,272 Da, 8 Da smaller than the reduced sample.

48

Figure 14. C1C2 H2031C/V2294C SEC purification. A) SEC chromatogram, two peaks were
eluted from the column, the first peak, denoted with a red star, was ran on a gel, but no bands
were detected (the 260/280 ratio for this peak was found to be ~3 suggesting that this peak is a
DNA contaminant), while the second peak denoted with a yellow star, was eluted at the
expected volume for the C1C2 construct. B) SDS-PAGE gel of the two SEC peaks, the C1C2
H2031C/V2294C collected from the second peak is boxed in yellow.

Antibody Growth and Purification
Antibody growth and purification was attempted with two anti-C1 mAbs (B136, M6143)
and five anti-A2 mAbs (4A4, 4F4, 1-D4, 2-101, 4C7). Hybridoma cells expressing the murine
derived B136 and M6143 were successfully cultured, however there was little to no expression
observed. This is likely due to improper storage of the hybridoma cells at -80 cC rather than in
liquid nitrogen, as well as irregular temperatures due to freezer electrical issues. The five antiA2 mAbs were successfully cultured and expressed and are now kept in proper storage
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conditions. Cell culture begins in Medium E, a fetal bovine serum-based media and contains a
variety of bovine proteins, including antibodies. These additional proteins make purification of
the target mAb next to impossible. To combat this, cells are passaged into Animal Origin Free
(AOF) media, which allows for easy purification from the media. Cell growth and expression
were tracked by consumption of nutrients via an acidic byproduct which results in a color shift
in the indicator containing media, as well as via visual cell adherence.
An additional shortage we encountered due to supply chain issues was T-75 cell growth
flasks. As such flask recycling was developed to continue antibody production. Here, either AOF
or MedE flasks underwent cell sloughing and these cells were removed followed by the addition
of additional media. This practice was found to be successful, however not a replacement for
regular cycling of growth flasks.
Upon mAb harvesting the media was diluted with buffer and purified with protein A
resin, which binds to IgG2 antibodies. Antibodies were then successfully cleaved via papain
αk

and optimized to occur overnight at 37 C. The subsequent Fab purification was also
c

consistently successful (Figure 15).
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Figure 15. Antibody purification and cleavage. A) SDS-PAGE gel image showing flow through
(FT) wash and elution steps in the purification of 4C7, 4A4, and 4F4, IgG heavy and light chains
are marked by black arrows. B) SDS-PAGE gel image showing a pre-IgG cleavage sample vs. a
cleaved and purified Fab sample

SAXS
Formation of ET3i in complex with anti-A2 inhibitory antibodies and subsequent
purification via SEC was successful. Usable SAXS data was collected at the ALS beamline and
processed for the ET3i:G99, ET3i:G99:4F4, ET3i:G99:4A4 complexes by Dr. Kenny Childers. The
known ET3i:G99 crystal structure (PDB #7KBT) was superimposed into the generated SAXS
envelopes to examine validity of the envelopes and identify the location of 4A4 and 4F4 within
the envelope (Figure 16). These envelopes illustrate the presence of additional density outside
of ET3i at the expected position for G99, as well as additional densities protruding from the A2
domain in the 4A4 and 4F4 containing constructs.
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Figure 16. SAXS data generated for ET3i, and the ET3i:G99, ET3i:G99:4F4, ET3i:G99:4A4
complexes. A) Pair distance distribution function (P(r)), illustrating the probability of any two
points A and B to be X distance apart, as well as the radius of gyration (Rg) and maximum
distance between atoms (dmax) used when calculating the P(r) for the ET3i:G99 (green),
ET3i:G99:4F4 (magenta), and ET3i:G99:4A4 (blue) complexes B) Images of the ET3i:G99 crystal
structure superimposed on the generated SAXS envelopes for the ET3i:G99 (green),
ET3i:G99:4F4 (magenta), and ET3i:G99:4A4 (blue) complexes. (Data work-up done by Dr. Kenny
Childers).
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Crystallography
Anti-A2 inhibitor Fabs of 4A4, 4F4, and 4C7 were screened in house using Hampton
Research screens. These generated crystal hits were further pursued with fine screening, and
crystals were looped and sent for data collection at the ALS beamline. Lower quality diffraction
was detected for two 4F4 crystals, and seven 4A4 crystals of varying conditions. A single 4A4
crystal generated higher quality diffraction with a 2.08 Å resolution (Figure 17). This crystal was
grown via hanging drop vapor diffusion in 0.2 M calcium chloride dihydrate and 20% PEG 3350.
As this illustrated the 4A4 Fab’s ability to produce high quality crystals, the ET3i:4A4 alongside
the C1:NB2E9 complex were sent to the Hauptman-Woodward Institute for a 1536 condition
crystal screen. A variety of fine screens were designed based on these large screens for both
complexes. At the time of writing C1:NB2E9 crystals have been looped and sent to the ALS
beamline, but failed to diffract, and the ET3i:4A4 conditions have just begun to be plated.

53

Figure 17. Fab crystallization and diffraction. A) Examples of
Fab crystals produced for 4A4, 4F4, and 4C7. Note, none of
these specific crystals produced usable diffraction data. B)
Diffraction data collected for 4A4 Fab with resolution of 2.08
Å.

Nanodisc Prep
MSP1D1 80:20 (PC:PS) nanodiscs were successfully constructed following protocols
designed by previous graduate students. The formed nanodiscs were then further purified via
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SEC, and the various fractions’ binding affinities for C1C2 WT were determined and the
fractions pooled based on similar levels of binding affinity (Figure 17). Pooled fractions were
stored at 4 °C, for future use in lipid binding studies.

Figure 17. Nanodisc purification. A) SEC of MSP1D1 80:20 (PC:PS) nanodiscs. Three separate
peaks were collected and accessed for binding to C1C2 WT via BLI, denoted by the red, purple,
and black stars. B) BLI binding curves of the collected fractions and C1C2 WT. Fractions were
pooled based on having similar levels of binding, denoted by the black, purple, and red boxes,
which also correspond to the elution peaks of the respective fractions (matched by color of star
and box).

Biolayer Interferometry
Initial BLI binding data was collected and used to confirm the identity and fold of the
disulfide mutants, by collecting binding data between the mutants and the anti-C1 NB2E9 and
anti-C2 BO2C11 inhibitors. Each of the disulfide mutants illustrated binding to both NB2E9 and
BO2C11 to a similar degree as the WT sample tested (figure 18). Initial BLI binding data was
collected and used to verify the identity of the anti-A2 antibodies by showing binding to ET3i.
Each of the five anti-A2 inhibitors illustrated binding to ET3i, with varying degrees of binding
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with 1-D4 and 4A4 showing the highest binding affinities followed by 4F4, and 2-101, with 4C7
having little to no additional binding in comparison to the blank (figure 19). As neither of these
experiments were conducted with varying protein concentration nor in triplicate, exact binding
capacities are unable to be determined. Regardless of not determining exact binding, binding
affinity was confirmed.

Figure 18. C1C2 disulfide mutants’ antibody test binding. A) C1C2 disulfide mutants’ test
binding to anti-C2 inhibitor NB2C11, with mutations and negative control labeled on the chart.
B) disulfide mutants’ test binding to anti-C1 inhibitor NB2E9, with mutations and negative
control labeled on the chart with the same color scheme as A.
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Figure 19. All five anti-A2 inhibitors’ test binding to ET3i to confirm identity and binding to FVIII,
with inhibitors and negative control labeled on the chart.

Discussion
FVIII’s C domains facilitate binding to the surface of activated platelet membranes,
allowing for the formation of the tenase complex. Binding models proposed have illustrated the
importance of both electrostatic interactions between positively charged basic residues of FVIII
and negatively charged PS headgroups, as well as the hydrophobic solvent exposed loops of the
C1 and C2 domains embedding into the anhydrous inner membrane coordinating and stabilizing
this lipid binding interaction. The data generated to build these binding models has focused
primarily on the C2 domain; however, there are implications for the importance of the C1
domain. Notably, the C2 domain appears to have a great degree of flexibility, having been
shown to rotate ~35-45o about a central set of residues. This flexibility is thought to perhaps
illustrate a docking and undocking conformation of the C2 domain 45. This flexibility alongside
the lone C2 constructs lack of PS specificity, while a C2 deleted FVIII construct retains PS
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specificity indicates the possibility of the C1 domain coordinating the initial binding interaction
followed by a conformational shift of the C2 domain causing it to swing down and stabilize the
lipid binding interaction. Additionally, the C2 domain sees a near complete loss of lipid binding
at physiological concentrations of NaCl, while full length FVIII retains binding approximately
equivalent to the C2 deleted construct64. This illustrates the importance of electrostatic
interactions in facilitating C2 lipid binding and shows that there are differences between the C1
and C2 domains’ mechanism of binding as well as possible regulation mechanisms.
Previous attempts to express soluble C1C2 and C1 constructs have been attempted by
other labs but were unsuccessful79. Through the addition of a Trx solubility tag and expression
in a modified SHuffle T7 vector that has been optimized to promote slow protein expression
alongside proper folding in disulfide-containing proteins and native disulfide bond formation 80
has proved to be successful in producing constructs that are properly folded while being
retained in the soluble fraction. Despite this, purification of any C1-containing construct is
plagued by a persistent 70 kDa contaminant, not seen in C2 constructs, that was unable to be
removed using typical wash buffers of more than 50 column volumes. This contaminant is
thought to be a chaperone (HSP70) that is naturally expressed in E. coli, which recognizes and
binds to the large, solvent exposed hydrophobic region (~1400 Å2) of C1. Additionally, the
three-fold larger hydrophobic region of C1 vs. C2 may help to explain poor solubility seen for C1
when compared to C2. The mechanism of chaperone release is driven by the phosphorylation
of the chaperone by ATP, as well as interaction with one K+ and two Mg2+ ions. As such, MgCl2
and KCl were added to the growth media to help prevent initial binding of sample to the
chaperone, and a purification protocol was developed which included an ATP wash step (also
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containing MgCl2 and KCl). This modified expression and purification protocol proved to be
extremely successful at removing this troublesome contamination, notably being shown to
work for five different C1C2 mutants and three different C1 mutants. This is of note, to further
our understanding of FVIII’s lipid binding mechanism, studies will need to investigate the C1
domain. The C2 domain has thus far been the primary protein of study for FVIII’s lipid
interactions, this is in part due to the ease of expression, solubility, and stability of this protein
in comparison to the C1 domain. Our expression and purification protocol’s seemingly universal
application to mutant C1 containing constructs illustrates a methodology that allows for
mutational studies at a wide variety of residues. This shows promise moving forward in our
understanding of C1’s role in the lipid binding mechanism.
The flexibility of the C2 domain points to the possibility of a docking and undocking
conformation. Four different C1C2 mutant constructs were designed and ordered such that if a
disulfide bond were to form between the mutation sites, it would lock C2 in its proposed
undocking conformation. Each of the four mutants were able to be successfully expressed and
purified. The identity and proper fold of each of the constructs was confirmed via binding to
anti-C1 and anti-C2 inhibitors via BLI, and molecular weight was confirmed on MS. The WT
C1C2-Trx construct contains 3 native disulfide bonds (2 within C1C2 and 1 in Trx). Formation of
a disulfide bond can be observed by a loss of 2 Da per bond in the overall mass of the construct.
The formation of a 4th disulfide bond, not seen in WT, was observed in the H2031C/V2294C
C1C2 mutant by an 8 Da shift between reduced and non-reduced samples illustrating success in
the formation of the designed disulfide bond. The mutant in question is an excellent candidate
to lock C1C2 in its undocking conformation, as the distance between the alpha carbons of
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H2031 and V2294 shifts from 5.4 Å to 10.2 Å from the undocking to docking conformations.
Moving forward with this project will require validating the location of this new disulfide bond,
determining reduction conditions that selectively break only this bond, and conducting lipid
binding assays to determine if there is a loss of binding when the designed disulfide bond is
present.
FVIII is an essential cofactor within the blood coagulation cascade, with those who have
a deficiency of functional FVIII having a condition known as hemophilia A. The most common
complication of hemophilia A treatment is the development of inhibiting antibodies that bind to
exogenous FVIII rendering it non-functional. The two most immunogenic domains of FVIII are
the C2 and A2 domains, with additional implications for the C1 domain. While there has been
extensive investigation of the immunogenic effects on the C2 domain, there has yet to be a
structure of an anti-A2 inhibitor bound to FVIII. There also has yet to be a structure of FVIII’s C1
domain in complex with a human derived antibody, which would provide validity to the
previous data collected using murine derived inhibitors when working with human models.
Unfortunately, despite obtaining diffraction data with a 2.08 Å resolution, the structure of the
4A4 Fab still needs to be solved as our lab has yet to receive the full sequence. Regardless, the
successful crystallization and diffraction of the 4A4 Fab is a promising start to being able to
obtain x-ray crystallographic data for the ET3i:4A4 complex. In addition, the successful
formation of the C1:human-derived-NB2E9 complex has allowed for a large-scale crystal
screening, with fine screens ongoing. As of writing there have been crystals looped and treated
with x-rays for the NB2E9 complex, however, there has yet to be any usable diffraction data.
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Beyond x-ray crystallography, SAXS data was collected for ET3i bound to anti-A2
antibodies 4A4 and 4F4, as well as anti-C2 G99, whose x-ray crystal structure bound to ET3i has
previously been determined. The generated SAXS envelopes for the ET3i:G99, ET3i:G99:4A4,
ET3i:G99:4F4 complexes matched previous structural data of the ET3i:G99 complex, with
additional density protruding from the A2
domain in the 4A4 and 4F4 containing
complexes. While the 4F4 epitope has yet to
be mapped, superimposing the 4F4 and 4A4
SAXS envelopes supports a partial overlap of
the 4A4 and 4F4 epitopes (Figure 20). The
4A4 binding epitope was previously
determined to be between residues Asp403His44455, however the exact binding, and
thereby method of FVIII inhibition, have yet
to be determined. Of the 403-444 FVIII
sequence there are two regions, 403-422
and 427-444, which are solvent exposed
with residues 423-426 completely buried
within the A2 domain. Within the
superimposed image of the two SAXS

Figure 20. Superimposition of
ET3i:G99:4F4, shown in purple, and
ET3i:G99:4A4, shown in blue, and ET3i:G99
crystal structure, with solvent exposed
residues in the proposed 4A4 binding
epitope labeled in red. (Data work up done
by Dr. Kenny Childers).

envelopes and the ET3i:G99 structure the
additional density presumed to be the 4A4 Fab appears to completely cover residues 403-422
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with some coverage of residues 427-444, while the 4F4 Fab appears to not cover residues 403422 with some coverage within residues 427-444 (Figure 20). Previous work has highlighted the
possibility of FVIII anti-A2 inhibitors blocking a potential FX binding site corresponding to
residues 400-409, resulting in loss of function in the tenase complex81. This may point to 4A4’s
method of inhibition, as well as explain why 4A4 is 121 times more immunogenic than 4F4
(Table 2), as it appears that 4F4’s binding epitope does not cover the 400-409 region. Again,
this data will contain greater insight once we have the sequences of both 4A4 and 4F4
alongside additional structural data of the 4F4 Fab and both of the inhibitors in complex with
ET3i.

Conclusions and Future Work
Hemophilia A is an X-linked recessive condition that affects 1 in 5,000 male births, most
commonly treated via venous injection of recombinant FVIII to act as a replacement for the
patients endogenous FVIII. Approximately 60-70% of patients are categorized as severe,
requiring frequent injections to stay on top of bleeding episodes. About a third of these severe
cases develop inhibiting antibodies during treatment which bind to the exogenous FVIII,
sterically hindering key binding partners from being able to bind to FVIII, thereby rendering it
non-functional. Looking forward in the development of FVIII therapeutics there are two main
considerations; minimizing the immunogenic response in patients, while maintaining proper
protein function. Gaining structural data of FVIII in complex with inhibitory antibodies provides
invaluable insight into the binding epitopes and thereby inhibitory mechanisms of these
antibodies. Knowing the key residues involved in inhibitor binding interactions may give way to
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designing therapeutics that are able to lower inhibitor binding capacity and thereby inhibition
of the therapeutic. To this extent continued efforts to obtain the first structure of FVIII in
complex with an anti-A2 inhibitor are ongoing, as well as obtaining the first structure of FVIII in
complex with a human-derived-anti-C1 inhibitor. Beyond identifying key residues involved in
inhibitor binding, structural data would be able to provide insight into inhibitor mechanism,
which can be used to extrapolate FVIII functional mechanisms, as seen in the development of
the current lipid binding model. Understanding FVIII’s mechanisms of function and the key
motifs therein, sets the stage for the needed pieces to construct a functional FVIII therapeutic.
With this in mind, efforts to confirm that the FVIII C2 domain’s flexibility corresponds to
a lipid docking and undocking conformation are ongoing. The next steps for this project first
require the validation of the location of the 4th disulfide bond observed in C1C2 mutant
H2031C/V2294C in order to show that it is in fact the designed disulfide bond. This could be
accomplished via simply sequencing the protein on a mass spectrometer, however due to the
relative high number of disulfide bonds present in the protein the data collection and work-up
might become too messy and complicated. Secondly, reducing conditions must be found such
that the two native disulfide bonds of C1C2 remain intact, while the non-native, designed
disulfide bond is broken. By combining this step alongside the first could prove to be a much
simpler task, by sequencing the protein after first alkylating the protein, to ‘mark’ any free
thiols, followed by reduction of the protein with varying reducing agents at differing
concentrations, followed by alkylation with a different alkylating agent of differing mass than
the first to separately ‘mark’ newly exposed thiols. By doing this one could observe which
cysteines make up the 4 disulfide bonds present in the protein, as well as compare which bonds
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are broken under varying reducing conditions. Thirdly, the lipid binding capacity of the
proposed docking and undocking conformations must be collected and compared. To do this
lipid binding affinity could be determined via BLI or lipid sedimentation assays using both the
protein treated with the proper reducing conditions to solely break the designed disulfide bond,
as well as a non-reduced protein sample.
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Appendix
C1C2_H2031C_V2294C_pET-32a(+)
MSDKIIHLTDDSFDTDVLKADGAILVDFWAEWCGPCKMIAPILDEIADEYQGKLTVAKLNIDQNPGTAPKYGIRGIPTLLL
FKNGEVAATKVGALSKGQLKEFLDANLAGSGSGHMHHHHHHSSGLVPRGSGMKETAAAKFERQHMDSPDLGTDDD
DKAMADIGSENLYFQSNSNKCQTPLGMASGCIRDFQITASGQYGQWAPKLARLHYSGSINAWSTKEPFSWIKVDLLAP
MIIHGIKTQGARQKFSSLYISQFIIMYSLDGKKWQTYRGNSTGTLMVFFGNVDSSGIKHNIFNPPIIARYIRLHPTHYSIRST
LRMELMGCDLNSCSMPLGMESKAISDAQITASSYFTNMFATWSPSKARLHLQGRSNAWRPQVNNPKEWLQVDFQK
TMKVTGVTTQGVKSLLTSMYVKEFLISSSQDGHQWTLFFQNGKVKVFQGNQDSFTPVCNSLDPPLLTRYLRIHPQSWV
HQIALRMEVLGCEAQDLY

C1C2_T2023C_V2294C__pET-32a(+)
MSDKIIHLTDDSFDTDVLKADGAILVDFWAEWCGPCKMIAPILDEIADEYQGKLTVAKLNIDQNPGTAPKYGIRGIPTLLL
FKNGEVAATKVGALSKGQLKEFLDANLAGSGSGHMHHHHHHSSGLVPRGSGMKETAAAKFERQHMDSPDLGTDDD
DKAMADIGSENLYFQSNSNKCQCPLGMASGHIRDFQITASGQYGQWAPKLARLHYSGSINAWSTKEPFSWIKVDLLAP
MIIHGIKTQGARQKFSSLYISQFIIMYSLDGKKWQTYRGNSTGTLMVFFGNVDSSGIKHNIFNPPIIARYIRLHPTHYSIRST
LRMELMGCDLNSCSMPLGMESKAISDAQITASSYFTNMFATWSPSKARLHLQGRSNAWRPQVNNPKEWLQVDFQK
TMKVTGVTTQGVKSLLTSMYVKEFLISSSQDGHQWTLFFQNGKVKVFQGNQDSFTPVCNSLDPPLLTRYLRIHPQSWV
HQIALRMEVLGCEAQDLY

C1C2_T2023_S2175_pET-32a(+)
MSDKIIHLTDDSFDTDVLKADGAILVDFWAEWCGPCKMIAPILDEIADEYQGKLTVAKLNIDQNPGTAPKYGIRGIPTLLL
FKNGEVAATKVGALSKGQLKEFLDANLAGSGSGHMHHHHHHSSGLVPRGSGMKETAAAKFERQHMDSPDLGTDDD
DKAMADIGSENLYFQSNSNKCQCPLGMASGHIRDFQITASGQYGQWAPKLARLHYSGSINAWSTKEPFSWIKVDLLAP
MIIHGIKTQGARQKFSSLYISQFIIMYSLDGKKWQTYRGNSTGTLMVFFGNVDSSGIKHNIFNPPIIARYIRLHPTHYSIRST
LRMELMGCDLNSCCMPLGMESKAISDAQITASSYFTNMFATWSPSKARLHLQGRSNAWRPQVNNPKEWLQVDFQK
TMKVTGVTTQGVKSLLTSMYVKEFLISSSQDGHQWTLFFQNGKVKVFQGNQDSFTPVVNSLDPPLLTRYLRIHPQSWV
HQIALRMEVLGCEAQDLY

C1C2_T2023C_L2324C_pET-32a(+)
MSDKIIHLTDDSFDTDVLKADGAILVDFWAEWCGPCKMIAPILDEIADEYQGKLTVAKLNIDQNPGTAPKYGIRGIPTLLL
FKNGEVAATKVGALSKGQLKEFLDANLAGSGSGHMHHHHHHSSGLVPRGSGMKETAAAKFERQHMDSPDLGTDDD
DKAMADIGSENLYFQSNSNKCQCPLGMASGHIRDFQITASGQYGQWAPKLARLHYSGSINAWSTKEPFSWIKVDLLAP
MIIHGIKTQGARQKFSSLYISQFIIMYSLDGKKWQTYRGNSTGTLMVFFGNVDSSGIKHNIFNPPIIARYIRLHPTHYSIRST
LRMELMGCDLNSCSMPLGMESKAISDAQITASSYFTNMFATWSPSKARLHLQGRSNAWRPQVNNPKEWLQVDFQK
TMKVTGVTTQGVKSLLTSMYVKEFLISSSQDGHQWTLFFQNGKVKVFQGNQDSFTPVVNSLDPPLLTRYLRIHPQSWV
HQIALRMEVCGCEAQDLY
Appendix Figure 1. Complete FVIII C1C2 Disulfide Mutant Construct Sequences. Sequences were
ordered from Genescript. FVIII C1C2 domain sequence is highlighted in green, thioredoxin in yellow, 6xHis tag in cyan, TEV cleavage site in grey, and mutations in red.
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Appendix Figure 2. C1C2 disulfide mutant purification. A) SDS-PAGE gel image of C1C2
T2023C/L2324C FPLC NI-NTA purification, with fraction number X labeled as f. X. Non-pure

samples are boxed in red and pure samples are boxed in yellow, corresponding to the red and
yellow stars on the chromatograph. B) Ni-NTA chromatogram of C1C2 T2023C, L2324C
purification, absorbance shown by the blue curve, and % buffer B shown by the orange curve.
The black star shows the end of the ATP wash and the elution of the 70 kDa contaminant, the
red star shows the beginning of elution off the column, matching the fractions boxed in red on
the gel image, and the yellow star shows the elution of the purified sample, corresponding to
the yellow boxed fractions on the gel image.
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Appendix Figure 3. C1C2 disulfide mutant purification. A) SDS-PAGE gel image of C1C2
T2023C/V2294C FPLC NI-NTA purification, with fraction number X labeled as f. X. Non-pure
samples are boxed in red and pure samples are boxed in yellow, corresponding to the red and
yellow stars on the chromatograph. B) Ni-NTA chromatogram of C1C2 T2023C, V2294C
purification, absorbance shown by the blue curve, and % buffer B shown by the orange curve.
The black star shows the end of the ATP wash and the elution of the 70 kDa contaminant, the
red star shows the beginning of elution off the column, matching the fractions boxed in red on
the gel image, and the yellow star shows the elution of the purified sample, corresponding to
the yellow boxed fractions on the gel image.
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Appendix Figure 4. C1C2 disulfide mutant purification. A) SDS-PAGE gel image of C1C2
H2031C/V2294C FPLC NI-NTA purification, with fraction number X labeled as f. X. Non-pure
samples are boxed in red and pure samples are boxed in yellow, corresponding to the red and
yellow stars on the chromatograph. B) Ni-NTA chromatogram of C1C2 H2031C, V2294C
purification, absorbance shown by the blue curve, and % buffer B shown by the orange curve.
The black star shows the end of the ATP wash and the elution of the 70 kDa contaminant, the
red star shows the beginning of elution off the column, matching the fractions boxed in red on
the gel image, and the yellow star shows the elution of the purified sample, corresponding to
the yellow boxed fractions on the gel image.
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Appendix Figure 5. Mass
chromatogram for C1C2 disulfide
mutants and wild type under nonreducing conditions. A) C1C2 WT,
showing a mass of 53,307 Da. B) C1C2
T2023C/V2294C. C) C1C2 T2023C,
S2175C, showing a mass of 54,366 Da.

75

